AXL-signaling has also been shown to prevent cytotoxic T-cells from binding and killing NSCLC cells (17) and is an important negative-feedback regulator of type I interferon-driven antitumor immunity (5), enabling cancers to resist ICI-mediated T-cell cytotoxicity in the long-term. Here, AXL is linked to cancer.